More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for...


More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for lab tests could disproportionately hurt BRLI due to its exposure to blood-based cancer tests — rates for lymphoma tests could rise 70% or more, analysts say. Also moving on the news is Quest Diagnostics (DGX +1.4%) which William Blair thinks will be the least affected, while shares of Neogenomics (NEO -15.4%) plummet on above average volume.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs